Please login to the form below

Not currently logged in
Email:
Password:

Merck

This page shows the latest Merck news and features for those working in and with pharma, biotech and healthcare.

Evenity back on track with FDA panel blessing in osteoporosis

Evenity back on track with FDA panel blessing in osteoporosis

It works in a very different way to existing drugs like bisphosphonate alendronate – sold by Merck/MSD as Fosamax – which works only by blocking bone destruction.

Latest news

  • EU approval for Opdivo combo in renal cell cancer EU approval for Opdivo combo in renal cell cancer

    However, the company has its IO rivals hot on its heels, with MSD’s Keytruda and Merck and Pfizer’s Bavencio both in late stage studies in combination with Pfizer’s

  • Chinese biotechs aim PD-L1 antibody at hepatitis B Chinese biotechs aim PD-L1 antibody at hepatitis B

    Front-runners in the immuno-oncology category such as Bristol-Myers Squibb (BMS) with Opdivo (nivolumab) and Merck &Co/MSD with Keytruda (pembrolizumab) have not started trialling their blockbuster drugs in ... Wang. BMS and Merck are both trying to

  • GSK upbeat on its return to oncology market GSK upbeat on its return to oncology market

    excellence. Can GSK make Tesaro assets shine? Analysts are sceptical that Zejula can make up ground on its biggest rival, Lynparza, the runaway market leader co-marketed by AstraZeneca and Merck

  • Moderna CEO makes case for firm’s lofty valuation Moderna CEO makes case for firm’s lofty valuation

    studies of candidates for respiratory syncytial virus (RSV) and a personalised cancer vaccine partnered with Merck &Co/MSD also at the planning stage. ... Other new studies coming up are phase 1 assessments of a triplet immuno-oncology drug (targeting

  • BMS and Celgene deal sparks debate on pharma profit motive, more M&A BMS and Celgene deal sparks debate on pharma profit motive, more M&A

    Two companies mentioned as potential likely buyers in the market are AbbVie and Merck &Co. ... Meanwhile Merck &Co has had enormous success with its immuno-oncology market leader Keytruda, but the rest of its portfolio is looking distinctly threadbare by

More from news
Approximately 341 fully matching, plus 1,229 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way ... This gives it a unique niche in an IO lung cancer market dominated

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    The Accelerated Access Collaborative. Ewan Barbour, Market Access and Pricing Director, Merck, presented on its multiple sclerosis treatment Mavenclad being selected to be among the first designated Rapid Uptake products on

  • Deal Watch October 2018

    The deal between Merck &Co and Samsung Bioepis has been in place since 2013, when Merck &Co began to work with Samsung Bioepis to produce biosimilars. ... Merck &Co has paid $155m to Samsung Bioepis to cover the investments made so far, plus interest, in

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it

More from intelligence
Approximately 8 fully matching, plus 122 partially matching documents found.

Latest appointments

More from appointments
Approximately 37 fully matching, plus 135 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 34 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics